[1] Dai JJ, Zhang YF, Zhang ZH. Global trends and hotspots of treatment for nonalcoholic fatty liver disease: A bibliometric and visualization analysis (2010-2023). World J Gastroenterol, 2023, 29(37): 5339-5360. [2] Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 2023, 77(4): 1335-1347. [3] Keating SE, Sabag A, Hallsworth K, et al. Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: a position statement from exercise and sport science Australia. Sports Med, 2023, 53(12): 2347-2371. [4] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023, 77(5): 1797-1835. [5] Shi YY, Liang YF. Prevalence and health management needs of non-alcoholic fatty liver disease in middle-aged and young people undergoing health check-ups: a survey. Heilongjiang Med Sci, 2022, 45(6): 161-162. [6] Chen G, Shuai XJ, Luo W, et al. Application of the“expert consensus on the management of important abnormal findings in health check-ups (trial version)”in health check-up centers. Health Check-up and Management, 2023, 4(2): 112-116. [7] Zheng Y, et al. External validation of fatty liver index and hepatic steatosis index in a large-scale Chinese physical examination cohort. BMJ Open, 2021, 11: e047822. [8] Razmpour F, Daryabeygi-Khotbehsara R, Soleimani D, et al. Application of machine learning in predicting non-alcoholic fatty liver disease using anthropometric and body composition indices. Sci Rep, 2023, 13: 4942. [9] Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr, 1991, 65(2): 105-114. [10] Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord, 2008, 6(4): 299-304. [11] Lim J, Kim J, Koo SH, et al. Comparison of triglyceride glucose index, and related parameters to predict insulin resistance in Korean adults: an analysis of the 2007-2010 Korean national health and nutrition examination survey. PLoS One, 2019, 14(3): e0212963. [12] Mansoori A, Nosrati M, Dorchin M, et al. A novel index for diagnosis of type 2 diabetes mellitus: cholesterol, high density lipoprotein, and glucose (CHG) index. J Diabetes Investig, 2025, 16(2): 309-314. [13] Wu J, Huang L, He H, et al. Red cell distribution width to platelet ratio is associated with increasing in-hospital mortality in critically ill patients with acute kidney injury. Dis Markers, 2022, 2022: 4802702. [14] ArefhosseiniS, Aghajani T, Tutunchi H, et al. Association of systemic inflammatory indices with anthropometric measures, metabolic factors, and liver function in non-alcoholic fatty liver disease. Sci Rep, 2024, 14: 12829. [15] Tosu AR, Biter H. Association of systemic immune-inflammation index (SII) with presence of isolated coronary artery ectasia. Arch Med Sci Atheroscler Dis, 2021, 6: e152-e157. [16] Millán J, Pintó X, Muñoz A, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag, 2009, 5: 757-765. [17] Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association. J Clin Lipidol, 2024, 18(5): e647-e663. [18] Qian X, Wu W, Chen B, et al. Value of triglyceride glucose-body mass index in predicting nonalcoholic fatty liver disease in individuals with type 2 diabetes mellitus. Front Endocrinol (Lausanne), 2025, 15: 1425024. [19] Huang X, Hu Y, Dong L, et al. TyG-BMI as a superior predictor of MAFLD and pre-MAFLD in Chinese adults: a cross-sectional study. BMC Gastroenterol, 2025, 25: 495. [20] Roh JH, Park JH, Lee H, et al. A close relationship between non-alcoholic fatty liver disease markerand new-onset hypertension in healthy Korean adults. Korean Circ J, 2020, 50(8): 695-705. [21] Åberg F, Kantojärvi K, Männistö V, et al. Association between arterial hypertension and liver outcomes using polygenic risk scores: a population-based study. Sci Rep, 2022, 12: 15581. [22] Kaya Eda,Yilmaz Yusuf.累及全身多系统的疾病:代谢相关(非酒精性)脂肪性肝病.中华肝脏病杂志,2025,33(1):77-87. [23] Huang H, Wang Q, Shi X, et al. Association between monocyte to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: across-sectional study. Mediators Inflamm, 2021, 2021: 6642246. [24] Wang L, Dong J, Xu M, et al. Association between monocyte to high-density lipoprotein cholesterol ratio and risk of non-alcoholic fatty liver disease: a cross-sectional study. Front Med (Lausanne), 2022, 9:898931. [25] Bril F, Barb D, Portillo-Sanchez P, et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology, 2017, 65(4): 1132-1144. [26] Zhao H, Fang Y, Zhao J, et al. Nonlinear relationship between body fat percentage and NAFLD mediated by METS-IR: threshold effects and subgroup differences. Sci Rep, 2025, 15: 24917. [27] 崔婷婷,安雪莲,孙德亮,等. 基于SHAP的可解释机器学习的滑坡易发性评价模型. 成都理工大学学报(自然科学版), 2025, 52 (01): 153-172. |